Core Viewpoint - Ningxia Zhongke Biotechnology Co., Ltd. is currently undergoing a restructuring plan, which may lead to a significant downward adjustment in its stock price due to potential capital reserve increases and other factors [2][3]. Group 1: Stock Price Risks - The company has indicated that its stock price may experience a downward adjustment of approximately 30% following the implementation of the restructuring plan, based on the closing price on December 3, 2025 [2][3]. - The adjustment in stock price will depend on the relationship between the closing price on the capital reserve increase registration date and the average price of the newly issued shares [3]. Group 2: Restructuring Uncertainties - The company has been ruled by the court to terminate the restructuring process and enter the execution phase of the restructuring plan, which carries the risk of being declared bankrupt if the plan is not executed [4]. - If the company is declared bankrupt, it will undergo liquidation, and its stock may face delisting according to the Shanghai Stock Exchange listing rules [4]. Group 3: Additional Risks - There are risks associated with the pre-restructuring investment agreements that have been signed, which may be terminated or become unenforceable [5]. - Other companies under the same group, such as Ningxia Zhongke New Materials Co., Ltd. and Ningxia Xinhai Hengli International Trade Co., Ltd., are also facing similar restructuring challenges and potential bankruptcy risks [6].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中科生物控股有限公司 呈交日期: 2025年12月2日 本月底法定/註冊股本總額： HKD 100,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01237 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 96,037,051 | | 0 | | 96,037,051 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 96,037,051 | | 0 | | 96,037,05 ...

Core Viewpoint - The announcement indicates a significant change in the ownership structure of Ningxia Zhongke Biological Technology Co., Ltd. due to the execution of its restructuring plan, resulting in Hunan Xinhong Pharmaceutical Co., Ltd. becoming the controlling shareholder and Liu Xirong as the actual controller [1][3][5]. Group 1: Basic Situation of the Equity Change - The court has approved the restructuring plan for the company, leading to the termination of its restructuring process [2][3]. - The total share capital of the company will increase from 684,883,775 shares to 1,615,883,775 shares after a capital reserve conversion, with 931,000,000 shares being issued [3][51]. - Hunan Xinhong will hold 357,142,857 shares, representing 22.10% of the total share capital post-conversion, thus becoming the controlling shareholder [1][5]. Group 2: Changes in Shareholding Structure - Before the equity change, Shanghai Zhongneng held 200,000,000 shares (29.20% of total shares), which will decrease to 12.38% after the change [5][17]. - The actual controller will shift from Yu Jianming to Liu Xirong following the equity change [5][49]. Group 3: Subsequent Matters - Hunan Xinhong and Shanghai Zhongneng are required to prepare equity change reports as per regulations [5][6]. - The restructuring investment involves a cash payment of 400 million yuan for the shares acquired by Hunan Xinhong, with a lock-up period of 36 months [51][60].

Core Viewpoint - The announcement details the progress of the second judicial auction of shares held by the controlling shareholder of Ningxia Zhongke Biotechnology Co., Ltd., indicating that the shares have been auctioned and the outcome is pending further legal procedures [2][4]. Group 1: Shareholding and Auction Details - Shanghai Zhongneng Enterprise Development (Group) Co., Ltd. holds 200,000,000 shares of Ningxia Zhongke, accounting for 29.20% of the total share capital, with all shares pledged and frozen [2][3]. - The second judicial auction for the 200,000,000 shares took place from November 17 to November 18, 2025, on the JD Network Judicial Auction platform [4][5]. - The auction results indicate that the shares were successfully bid on, with the final transaction subject to the court's auction ruling [5][6]. Group 2: Future Steps and Uncertainties - Following the auction, there are still steps involving the payment of auction proceeds, legal execution procedures, and the transfer of share ownership, which introduces uncertainty regarding the final outcome [2][6]. - If the shares are fully transferred, Shanghai Zhongneng will no longer hold any shares in the company [2][6]. - The company will closely monitor the situation and fulfill its information disclosure obligations as required by relevant laws and regulations [2][6].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中科生物控股有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01237 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000 | HKD | | 0.5 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 200,000,000 | HKD | | 0.5 | HKD | | 100,000,000 | 本月底法定/註冊股本總額 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責 ，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任 何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 | | 普通決議案 | 票數（概約%） | | | --- | --- | --- | --- | | | | 贊成 | 反對 | | 1. | 批准二零二五年股份獎勵計劃 | 26,052,697 | 20,000 | | | | (99.92%) | (0.08%) | | 2. | 批准服務提供商分項限額 | 26,052,697 | 20,000 | | | | (99.92%) | (0.08%) | CHINA ENVIRONMENTAL TECHNOLOGY AND BIOENERGY HOLDINGS LIMITED 中科生物控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1237） 股東特別大會投票表決結果 茲提述中科生物控股有限公司（「本公司」）日期為二零二五年九月二十二日的 通函（「通函」）。本公告所用詞彙與通函所界定者具有相同涵義。 董事會欣然宣佈，股東特別大會通告所載 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中科生物控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01237 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000 | HKD | | 0.5 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 200,000,000 | HKD | | 0.5 | HKD | | 100,000,000 | 本月底法定/註冊股本總額： ...

CHINA ENVIRONMENTAL TECHNOLOGY AND BIOENERGY HOLDINGS LIMITED 中科生物控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號: 1237) N O T I F I C AT I O N L E T T E R 通 知 信 函 26 September 2025 Dear non-registered shareholder(s), China Environmental Technology and Bioenergy Holdings Limited (the "Company") - Notice of Publication of 2025 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company has been published in E ...

CHINA ENVIRONMENTAL TECHNOLOGY AND BIOENERGY HOLDINGS LIMITED 中科生物控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號: 1237) By order of the Board China Environmental Technology and Bioenergy Holdings Limited Xie Qingmei Chairlady N O T I F I C AT I O N L E T T E R 通 知 信 函 Dear registered shareholder(s), 26 September 2025 China Environmental Technology and Bioenergy Holdings Limited (the "Company") - Notice of Publication of 2025 Interim Report (the "Current ...

Revenue and Profitability - The Group's revenue increased by 7.0% to RMB199.5 million during the first half of 2025, compared to RMB186.5 million in the same period of 2024[12]. - Revenue for the six months ended June 30, 2025, increased by 6.8% to RMB199.5 million compared to RMB186.5 million in the same period of 2024[22]. - Revenue from wooden products, the largest income stream, accounted for 99.3% of total sales, with an increase to RMB198.1 million from RMB185.4 million[22]. - Revenue from renewable energy products rose by 34.1% to approximately RMB1.4 million, up from RMB1.1 million in 2024[23]. - The Group recorded a profit of approximately RMB8.8 million for the period, a turnaround from a loss of RMB1.7 million in 2024[34]. - Profit for the period attributable to owners of the Company was RMB8,752,000, a significant recovery from a loss of RMB1,715,000 in the prior year[117]. - Total comprehensive income for the period was RMB12,525,000, up from RMB4,302,000 in the previous year, reflecting a year-over-year increase of approximately 191%[119]. - The reportable segment profit for the six months ended June 30, 2025, was RMB7,290,000, compared to a loss of RMB347,000 in the same period of 2024, indicating a significant turnaround[160]. Cost and Expenses - Selling and distribution expenses decreased by 39.1% to RMB6.6 million, compared to RMB10.8 million in 2024[26]. - Administrative expenses increased to RMB18.4 million from RMB18.0 million, mainly due to higher research and development costs[31]. - Finance costs decreased to approximately RMB3.6 million from RMB8.8 million, reflecting lower interest payments on bank loans[32]. - Research and development costs for the six months ended June 30, 2025, were RMB4,435,000, down from RMB5,410,000 in 2024, a decrease of 18%[168]. Assets and Liabilities - As of June 30, 2025, current assets were RMB535.4 million, with cash and cash equivalents at RMB33.8 million[35]. - Total liabilities increased to RMB378,288,000 from RMB335,972,000, reflecting a rise of approximately 12.5%[122]. - The company's equity increased to RMB887,381,000 as of June 30, 2025, compared to RMB874,856,000 at the end of 2024, showing a growth of about 1.5%[122]. - The company reported an increase in trade and other receivables to RMB190,680,000 from RMB157,009,000, which is an increase of approximately 21.5%[121]. - The Group's inventories totaled RMB114,538,000 as of June 30, 2025, down from RMB123,652,000 as of December 31, 2024[178]. Market and Economic Environment - The overall economic environment remains unstable, affecting customer purchasing behavior and market dynamics[18]. - The outlook for Chinese wooden product exports in 2025 is cautiously optimistic, driven by a rebound in global housing demand and cross-border e-commerce growth[53]. - Manufacturers face significant challenges including stringent EU sustainability regulations, persistent U.S. tariffs, and intense competition from Southeast Asian producers[55]. Strategic Focus and Future Outlook - The Group's core business segments remain focused on manufacturing wooden products and renewable energy, with a strategic emphasis on sustainability[17]. - The Group continues to explore opportunities for market expansion and product development in response to changing market conditions[19]. - Future outlook includes a commitment to improving operational efficiency and enhancing product offerings to meet customer demands[19]. Shareholder Information and Corporate Governance - As of June 30, 2025, Mr. Wu Zheyan holds a total of 20,452,488 shares, representing approximately 22.20% of the total shareholding[64]. - The Company proposed to adopt the 2025 Share Award Scheme, which will also be valid for ten years from the adoption date[100]. - The Company did not declare any interim dividend for the period[103]. - The audit committee has reviewed the unaudited interim financial report for the period, ensuring compliance with accounting principles and policies[112]. - The Company has complied with the Corporate Governance Code, except for specific provisions regarding board meeting frequency and management updates[105][106]. Cash Flow and Financing Activities - The cash flow from operating activities showed a net cash outflow of RMB6,188,000 for the six months ended June 30, 2025, compared to a net cash inflow of RMB20,811,000 in the same period of 2024[127]. - The company incurred a net cash outflow of RMB28,089,000 from investing activities during the first half of 2025, compared to a net cash outflow of RMB76,011,000 in the same period of 2024[128]. - The net cash from financing activities was RMB40,766,000 for the six months ended June 30, 2025, an increase from RMB36,296,000 in the same period of 2024[128]. Segment Information - The Group has identified two reportable segments: Manufacturing and sales of wooden products, and Manufacturing and sales of renewable energy products, with no aggregation of operating segments[149]. - Revenue from external customers in the manufacturing and sales of wooden products segment increased to RMB198,090,000 in 2025 from RMB185,431,000 in 2024, reflecting a growth of 6.5%[159]. - The Group's revenue recognition is based on products transferred at a point in time, with all revenue recognized in this manner for both segments[145].